{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/management/trunk-limbs/","result":{"pageContext":{"chapter":{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs","depth":2,"htmlHeader":"<!-- begin field db23b397-67c4-4a44-a776-e74226e1750b --><h2>Scenario: Trunk and limbs</h2><!-- end field db23b397-67c4-4a44-a776-e74226e1750b -->","summary":"Covers the management of chronic plaque psoriasis of the trunk and limbs in primary care.","htmlStringContent":"<!-- begin item 8c59f3a0-0c58-409c-b41a-88a6b4d13a42 --><!-- begin field 7480809e-4db3-4c3a-b223-acbc015bb2b4 --><p>From age 18 years onwards.</p><!-- end field 7480809e-4db3-4c3a-b223-acbc015bb2b4 --><!-- end item 8c59f3a0-0c58-409c-b41a-88a6b4d13a42 -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"1fda4a8f-aee8-5511-985d-d2d7016e3824","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 24e35f30-3fb1-4a3c-a694-c1999c7495b9 --><h3>How should I manage chronic plaque psoriasis of the trunk and limbs?</h3><!-- end field 24e35f30-3fb1-4a3c-a694-c1999c7495b9 -->","summary":null,"htmlStringContent":"<!-- begin item 4e6550b5-54e0-40db-83e5-fb186c08b278 --><!-- begin field 441277d1-ec30-49bb-b014-6ab9b721dac2 --><p><strong>If the person has <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#chronic-plaque-psoriasis\">chronic plaque psoriasis</a> of the trunk and/or limbs:</strong></p><ul><li>Offer advice on the nature of psoriasis, and explain that treatment is aimed at control of symptoms rather than cure, and that complete clearance of skin lesions may not be possible.</li><li>Reassure that it is not an infectious condition, and provide advice on sources of information and support, such as:<ul><li>The Psoriasis and Psoriatic Arthritis Alliance (PAPAA; website available at <a data-hyperlink-id=\"5941bec6-6dd9-4a76-8dcd-a93100a17e9c\" href=\"http://www.papaa.org/\" target=\"_blank\">www.papaa.org</a>) is a national charity which provides information and advice on all aspects of psoriasis and psoriatic arthritis, including a leaflet on <a data-hyperlink-id=\"c7ce7c53-23d2-4d1a-b320-a93100a17fab\" href=\"http://www.papaa.org/sites/default/files/What_is_psoriasis.pdf\" target=\"_blank\">What is psoriasis?</a>.</li><li>The Psoriasis Association (website available at <a data-hyperlink-id=\"784d774e-70ae-43ab-8200-a93100a17fb0\" href=\"https://www.psoriasis-association.org.uk/\" target=\"_blank\">www.psoriasis-association.org.uk</a>) is a national charity and membership organization for people affected by psoriasis.</li><li>The British Association of Dermatologists information leaflet on <a data-hyperlink-id=\"0bc25076-40e2-4078-b00e-a93100a17fbe\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=178&itemtype=document\" target=\"_blank\">Psoriasis - an overview</a>.</li><li>The NHS patient leaflet on <a data-hyperlink-id=\"db65d20d-0185-4ea8-9004-a93100a1801b\" href=\"https://www.nhs.uk/conditions/psoriasis/\" target=\"_blank\">Psoriasis</a>.</li></ul></li><li>Give general lifestyle advice to reduce the risk of exacerbations, such as advice on:<ul><li>Smoking cessation if appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for more information.</li><li>Drinking alcohol within recommended limits. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> for more information.</li><li>Weight loss if the person is overweight or obese. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information. The PAPAA has an information leaflet on <a data-hyperlink-id=\"72061d91-6ac1-4c91-935c-a93100a18024\" href=\"http://www.papaa.org/sites/default/files/Psoriatic_lifestyle_and_nutrition.pdf\" target=\"_blank\">Psoriatic lifestyle and nutrition</a>.</li></ul></li><li>Assess for associated stress, distress, anxiety and/or depression, and manage appropriately. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.<ul><li>The PAPAA has an information leaflet on <a data-hyperlink-id=\"5cc90f9d-38ba-4b27-9632-a93100a1802a\" href=\"http://www.papaa.org/sites/default/files/Psychological%20aspects%20of%20psoriasis%20final%20May%202015.pdf\" target=\"_blank\">Psychological aspects of psoriasis</a>.</li></ul></li><li>Offer treatment with <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#topical-drug-treatment\">topical preparations</a>, depending on the person's preferences, cosmetic acceptability, practical aspects of application, and the site(s) and extent of psoriasis to be treated.<ul><li>The PAPAA has an information leaflet on <a data-hyperlink-id=\"21a18964-fe76-4bc8-aadb-a93100a1802e\" href=\"http://www.papaa.org/sites/default/files/Treatments_Psoriasis_2017.pdf\" target=\"_blank\">Treatments for psoriasis: an overview</a>.</li><li>The British Association of Dermatologists has an information leaflet on <a data-hyperlink-id=\"2725db83-7cc3-48c5-b853-a93100a18033\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=123&itemtype=document\" target=\"_blank\">Topical treatments for psoriasis</a>.</li><li>Advise that topical treatments may take several weeks to start to work, and if treatment is stopped suddenly, there may be a risk of relapse.<ul><li>Creams, lotions, or gels are suitable for widespread psoriasis.</li><li>Ointments are suitable for areas of skin with thick scale.</li><li>Lotions, solutions, or gels are suitable for hair-bearing areas.</li></ul></li><li>Topical corticosteroids are only suitable for treating localized areas of psoriasis. Note: repeat prescriptions for topical corticosteroids should be carefully reviewed and supervised to identify any adverse effects, and to avoid use on widespread psoriasis where there is a risk of unstable disease.</li></ul></li><li>Arrange to review the person within four weeks after treatment has started and regularly thereafter, depending on clinical judgement, to:<ul><li>Assess the initial response to treatment, including the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">severity and impact</a> of psoriasis.</li><li>Assess for any issues with topical application or adverse effects.</li><li>Reinforce the importance of adherence to treatments.</li></ul></li><li>Advise the person to seek urgent medical advice if they experience unexplained joint pain or swelling, as this may be a sign of <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a> that requires specialist referral.</li><li>Arrange to review the person at least annually if they are using multiple intermittent or short-term courses of potent topical corticosteroids to:<ul><li>Optimize treatment and assess for adverse effects such as skin atrophy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information.</li><li>Assess disease <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">severity and impact</a>, and assess for new joint symptoms that may suggest psoriatic arthritis, and arrange specialist referral if appropriate.</li><li>Note: seek urgent specialist dermatology advice if there is any uncertainty about adverse effects or drug safety if the person is taking <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#specialist-assessment-management\">specialist drug treatments</a>.</li></ul></li><li>Assess the person's risk of cardiovascular disease at least every five years, especially if psoriasis is severe, depending on clinical judgement. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.<ul><li>The PAPAA has an information leaflet on <a data-hyperlink-id=\"08121808-aaa0-4a6a-b0ac-a93100a18042\" href=\"http://www.papaa.org/sites/default/files/Ps%20and%20the%20heart%20final.pdf\" target=\"_blank\">Psoriasis and the heart</a>.</li></ul></li><li>Advise the person on how to reduce the risk of venous thromboembolism, especially if psoriasis is severe. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/deep-vein-thrombosis/\">Deep vein thrombosis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/dvt-prevention-for-travellers/\">DVT prevention for travellers</a> for more information.</li></ul><!-- end field 441277d1-ec30-49bb-b014-6ab9b721dac2 --><!-- end item 4e6550b5-54e0-40db-83e5-fb186c08b278 -->","subChapters":[{"id":"19259121-7a66-50ce-a2ec-17937ed52bf4","slug":"basis-for-recommendation-f11","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 29bc7df9-b8b3-424f-b15b-cd9e72edc6d3 --><h4>Basis for recommendation</h4><!-- end field 29bc7df9-b8b3-424f-b15b-cd9e72edc6d3 -->","summary":null,"htmlStringContent":"<!-- begin item f11ab6f8-fda1-4780-a994-319a20975f41 --><!-- begin field 50ff3963-6d5c-4c5a-a80a-b487f7bb2145 --><p>The recommendations on management are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>], a systematic review on weight loss intervention on disease severity of psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Upala, 2015</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</p><h5>Giving lifestyle advice</h5><ul><li>The recommendation on lifestyle and weight loss advice is based on a systematic review of five randomized controlled trials (RCTs; number of participants not specified) which found strong evidence of a greater reduction in psoriasis severity scores in overweight or obese people receiving weight loss intervention (by diet or exercise) than a control group. The meta-analysis was limited, however, by the small number of included studies, the short follow-up period, and heterogeneity between studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Upala, 2015</a>].</li></ul><h5>Arranging annual review</h5><ul><li>The recommendations on annual review are largely based on the SIGN clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>].</li><li>The recommendation on seeking specialist dermatology advice if there is any uncertain about safety or appropriateness of specialist drug treatment is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Assessing cardiovascular disease risk</h5><ul><li>People with severe psoriasis are at increased cardiovascular risk, so these people should be screened using appropriate risk assessment tools to allow early management of modifiable risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</li></ul><!-- end field 50ff3963-6d5c-4c5a-a80a-b487f7bb2145 --><!-- end item f11ab6f8-fda1-4780-a994-319a20975f41 -->","subChapters":[]}]},{"id":"696cba86-8e56-558c-bd0f-fcfac9a418b9","slug":"topical-drug-treatment","fullItemName":"Topical drug treatment","depth":3,"htmlHeader":"<!-- begin field 5e0a5dd2-37fd-47b0-a9bb-cbe6ec22692a --><h3>What topical drug treatments should I offer?</h3><!-- end field 5e0a5dd2-37fd-47b0-a9bb-cbe6ec22692a -->","summary":null,"htmlStringContent":"<!-- begin item 2407e93b-dc11-4cd0-b27f-324c2efa7b66 --><!-- begin field 5bc81b97-7965-4a8d-a2c6-2134503f4beb --><ul><li><strong>Offer treatment with topical preparations, and consider whether <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#referral\">referral</a> is needed if lesions are extensive, severe, or not responding to treatment. Options include:</strong><ul><li>An emollient to reduce scale and help relieve itch. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/emollients/\">Emollients</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a data-hyperlink-id=\"5e9982a1-c757-447a-905a-a93100a252f4\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Moisturisers.pdf\" target=\"_blank\">Moisturisers</a> or the Psoriasis and Psoriatic Arthritis Alliance leaflet on <a data-hyperlink-id=\"151f44d7-d0fd-4620-9ea9-a93100a25308\" href=\"http://www.papaa.org/sites/default/files/emollients_June_2016.pdf\" target=\"_blank\">Emollients and Psoriasis</a>.</li></ul></li><li>A potent topical corticosteroid plus a topical vitamin D preparation (both applied once a day, but at different times of day). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> and the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/vitamin-d-preparations/\">Vitamin D preparations</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Give advice on how to minimize the risk of corticosteroid adverse effects, such as stopping the topical corticosteroid once the skin is clear or nearly clear.</li><li>Provide advice on sources of information such as the Psoriasis Association leaflets on <a data-hyperlink-id=\"45bbc84c-e1d3-4262-a42b-a93100a253a2\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Steroids.pdf\" target=\"_blank\">Topical steroids</a> and <a data-hyperlink-id=\"49d1308e-e8f3-4100-888b-a93100a253ab\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Vitamin_D.pdf\" target=\"_blank\">Vitamin D</a>.</li><li>Note: very potent corticosteroid preparations should not normally be used in primary care, due to the risk of adverse effects.</li></ul></li><li>Consider a salicylic acid preparation if scale is problematic. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/salicylic-acid/\">Salicylic acid</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li><strong>Review the person after four weeks:</strong><ul><li>If there has been a good initial response, continue topical treatment until the skin is clear or nearly clear.</li><li>Advise the person <em>not </em>to apply potent corticosteroids for more than eight weeks at any one site.<ul><li>Treatment may be restarted after a four-week 'treatment break' — during this time topical vitamin D preparations may be continued.</li></ul></li><li>Advise that courses of topical treatments (including corticosteroids) can be used as needed to maintain satisfactory control of psoriasis, reinforcing the advice on the safe use of potent topical corticosteroids.<ul><li>Offer a prescription for topical treatments to allow self-management on an as-needed basis.</li></ul></li></ul></li><li><strong>If there is a poor initial response after the first four weeks:</strong><ul><li>Check adherence to treatment, and ask about any issues with application, cosmetic acceptability, or tolerability of topical treatments.</li><li>If there is no obvious explanation for treatment failure, consider:<ul><li>Continuing treatment with a potent topical corticosteroid plus a topical vitamin D preparation (both applied once a day, but at different times of day) for another four weeks <em>or</em></li><li>Stopping the potent corticosteroid and only applying a topical vitamin D preparation twice a day for up to 12 weeks.</li></ul></li></ul></li><li><strong>If there is a poor response after an additional four weeks </strong>of treatment with a potent corticosteroid plus a vitamin D preparation (eight weeks treatment in total):<ul><li>Advise the person to stop the potent corticosteroid and only apply a vitamin D preparation twice a day.</li></ul></li><li><strong>If there is still a poor response after 8–12 weeks of treatment with a vitamin D preparation alone twice a day, offer</strong><strong>:</strong><ul><li>A potent corticosteroid, applied twice a day for up to 4 weeks, <em>or</em></li><li>A coal tar preparation applied once or twice daily. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/coal-tar-products/\">Coal tar products</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a data-hyperlink-id=\"a808c3ab-ed0b-4096-95e2-a93100a253b5\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Coal_Tar.pdf\" target=\"_blank\">Coal Tar Applications</a>.</li></ul></li></ul></li><li><strong>If there is ongoing treatment failure:</strong><ul><li>Consider offering a combined topical preparation containing a potent corticosteroid and vitamin D, applied once a day for up to four weeks.</li></ul></li><li><strong>If there is ongoing treatment-resistant psoriasis:</strong><ul><li>Consider whether there may be an <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/differential-diagnosis/\">alternative diagnosis</a>, and manage appropriately.</li><li>Offer treatment with short-contact dithranol if educational support for self-use can be given. The Psoriasis Association leaflet on <a data-hyperlink-id=\"53a10808-5de9-410e-99cb-a93100a253ba\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Dithranol.pdf\" target=\"_blank\">Dithranol</a> may be helpful. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/dithranol-short-contact/\">Dithranol - short contact</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information, <em>or</em></li><li>Arrange <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#referral\">referral</a> to a dermatologist for specialist assessment and management.</li></ul></li></ul><!-- end field 5bc81b97-7965-4a8d-a2c6-2134503f4beb --><!-- end item 2407e93b-dc11-4cd0-b27f-324c2efa7b66 -->","subChapters":[{"id":"b8b944e1-16e9-58df-8cef-091a1359ef4a","slug":"basis-for-recommendation-002","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9bc30bd6-9816-47d5-b5b1-f65185dcaa9e --><h4>Basis for recommendation</h4><!-- end field 9bc30bd6-9816-47d5-b5b1-f65185dcaa9e -->","summary":null,"htmlStringContent":"<!-- begin item 0025f80f-d877-4196-ad5f-9c0c634bcd60 --><!-- begin field cf5ea5e5-d7f6-4d78-be15-8af28bef7ec9 --><p>The recommendations on topical drug treatments are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], a Cochrane systematic review <em>Topical treatments for chronic plaque psoriasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Mason, 2013b</a>], a systematic review on topical therapies for the treatment of plaque psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2013</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Jabbar-Lopez, 2014</a>].</p><h5>Choice of topical preparations</h5><ul><li>The recommendations on the use of emollients are based on the fact that they improve the skin's barrier function, reduce scale, and may increase the penetration and effectiveness of some active topical treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].</li><li>The recommendations on the choice and sequencing of active topical treatments are largely based on a clinical and cost-effectiveness analysis in the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].<ul><li>It concluded that combination therapy with a vitamin D analogue and potent corticosteroid was more effective than either agent alone. A combination product was the most effective treatment, however this was not recommended by NICE first-line, as it was not found to be cost-effective.</li><li>Very-potent corticosteroids were excluded from the analysis and are not generally recommended for primary care use due to concerns regarding their long-term safety profile, including risk of rebound effects, irreversible skin atrophy, and a lack of long-term safety data.</li><li>Twice daily coal tar was a potentially cost-effective option if the skin was not clear or nearly clear with other topical treatment.</li></ul></li><li>A Cochrane systematic review of 177 randomized controlled trials (RCTs; n = 34,808) found that vitamin D analogues and most corticosteroid preparations were significantly more effective than placebo. Head-to-head comparisons of vitamin D preparations compared with potent- or very-potent corticosteroids (not usually used in primary care) had mixed findings [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Mason, 2013b</a>]:<ul><li>Combination treatment with vitamin D and corticosteroids performed significantly better than vitamin D or corticosteroid monotherapy.</li><li>Vitamin D preparations generally performed better than coal tar, but findings relative to dithranol were mixed.</li></ul></li><li>An additional systematic review (not included in the Cochrane review) of 48 randomized studies found that corticosteroids are highly effective in treating plaque psoriasis when used continuously for up to eight weeks. It concluded that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2013</a>]:<ul><li>The combination of potent corticosteroid and vitamin D analogue, either applied once daily in a single product or applied separately, was the most effective intervention, with no significant difference between application methods.</li><li>Coal tar treatment was no better than placebo and is of limited clinical benefit.</li></ul></li><li>The recommendation to consider a salicylic acid preparation for thick scale is based on expert opinion in a review article on psoriasis that states salicylic acid may allow other active topical treatment to penetrate the skin more effectively, improving the absorption and efficacy of subsequently applied topical preparations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Jabbar-Lopez, 2014</a>].</li></ul><h5>Advising on corticosteroid 'treatment breaks'</h5><ul><li>The recommendation on corticosteroid 'treatment breaks' is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>] and on expert opinion in a review article on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>].<ul><li>The NICE guideline states that continuous use of potent- or very-potent topical corticosteroids can cause adverse effects such as irreversible skin atrophy, striae, and telangiectasia, and may cause psoriasis to become unstable, if applied to extensive areas.</li><li>The review article highlights that long-term corticosteroid use may lead to potential tachyphylaxis, where efficacy decreases over time, as well as adverse effects such as skin atrophy.</li></ul></li></ul><!-- end field cf5ea5e5-d7f6-4d78-be15-8af28bef7ec9 --><!-- end item 0025f80f-d877-4196-ad5f-9c0c634bcd60 -->","subChapters":[]}]},{"id":"a7c496bd-3fc1-5f4d-b8c5-4b52fcbc1432","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 06865341-427b-406e-ad43-858d1d69ed32 --><h3>When should I refer a person with chronic plaque psoriasis of the trunk and limbs?</h3><!-- end field 06865341-427b-406e-ad43-858d1d69ed32 -->","summary":null,"htmlStringContent":"<!-- begin item 0eb0303d-96bb-47e9-9da9-46d46454f7ae --><!-- begin field 91e28d33-1209-4b42-8709-097ee2c8bbb7 --><ul><li>If the person presents with suspected <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#pustular-psoriasis\">generalized pustular psoriasis</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#erythrodermic-psoriasis\">erythrodermic psoriasis</a>, this should be managed as a medical emergency:<ul><li>Arrange for urgent same-day specialist dermatology assessment and ongoing management.</li></ul></li><li>Arrange referral to a dermatologist for <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#specialist-assessment-management\">specialist assessment and management</a>, the urgency depending on clinical judgement, if:<ul><li>There is uncertainty about the diagnosis.</li><li>Psoriasis is extensive, for example more than 10% of the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">body surface area</a> is affected.</li><li>Psoriasis is at least moderately severe, as measured by the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">Physician&#39;s Global Assessment</a> tool.</li><li>Psoriasis is resistant to <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#topical-drug-treatment\">topical drug treatments</a> in primary care, or treatments are not tolerated.</li><li>There is a significant impact on the person's physical, psychological, or social wellbeing.</li><li>Additional information or education for self-use is needed (for example about application of topical treatments, such as short-contact dithranol).</li></ul></li><li>Arrange an urgent referral to a rheumatologist if a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a> is suspected.</li></ul><!-- end field 91e28d33-1209-4b42-8709-097ee2c8bbb7 --><!-- end item 0eb0303d-96bb-47e9-9da9-46d46454f7ae -->","subChapters":[{"id":"d73dd4ab-36ed-507d-aca2-e0de351ed894","slug":"specialist-assessment-management","fullItemName":"Specialist assessment and management","depth":4,"htmlHeader":"<!-- begin field b7f8b328-b77a-4bcd-998a-a80800adc72a --><h4>Specialist assessment and management</h4><!-- end field b7f8b328-b77a-4bcd-998a-a80800adc72a -->","summary":null,"htmlStringContent":"<!-- begin item 0bb89d41-9eee-4878-b548-a80800adc246 --><!-- begin field c653b54f-e072-434f-9f51-a80800adc72a --><p><strong>Dermatology treatments such as phototherapy, systemic drugs, or biologic therapy may be considered if psoriasis does not respond to topical treatments in primary care. Specialist treatments should be initiated and monitored by a specialist dermatology team. </strong>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/\">DMARDs</a> for more information.</p><h5>Skin biopsy</h5><ul><li>The diagnosis of psoriasis is usually based on clinical findings. In rare cases, a skin biopsy may be needed to differentiate psoriasis from other inflammatory skin conditions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Johnson, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</li></ul><h5>Topical calcineurin inhibitors</h5><ul><li>Drugs such as topical tacrolimus and pimecrolimus are typically used off-label for difficult-to-treat sites, such as flexural or facial psoriasis.</li><li>Provide advice on sources of information and support such as the British Association of Dermatologists leaflet on <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=155&itemtype=document\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"36f88629-f551-455a-bb69-a93100c0e97f\">Calcineurin inhibitors</a>.</li></ul><h5>Phototherapy</h5><ul><li>Narrow-band ultraviolet B (UVB) phototherapy is effective in treating refractory mild to moderate chronic plaque psoriasis or guttate psoriasis, and may be offered in preference to broad-band UVB and psoralen plus UVA (PUVA) phototherapy.<ul><li>Phototherapy has a complex mechanism of action, targetting skin immune cells and keratinocytes, causing epidermal remodelling and reduction of inflammation.</li><li>PUVA may be offered for localized pustular psoriasis.</li></ul></li><li>Treatment is usually offered two to three times a week, and the dose is based on the person's 'minimal erythema dose' and sun-reactive skin type, with a graded increase in dose according to response.</li><li>Provide advice on sources of information and support such as the Psoriasis Association patient leaflet on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/UV.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"e01a598b-f4dd-48d3-818c-a93100c0e988\">UV Therapy</a> and the British Association of Dermatologists leaflet on <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=124&itemtype=document\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"24217a57-39d5-4d83-bca2-a93100c0e996\">Treatments for moderate or severe psoriasis</a>.</li></ul><h5>Systemic therapy</h5><ul><li>Systemic drugs such as methotrexate, ciclosporin, and acitretin may be offered for severe or refractory plaque disease, nail disease, or psoriasis affecting high-impact sites (such as the face, genitals, hands and feet, scalp, or flexures).</li><li>They are typically used if phototherapy has been ineffective, is contraindicated, or has resulted in a rapid relapse of disease within 3 months.</li><li>Ensure the person is aware:<ul><li>About the possible effects of therapy during conception and pregnancy, and ensure the person is using effective contraception during and after treatment.</li><li>That live vaccines are contraindicated, and these vaccines should only be given before the start of specialist treatment, or else postponed for at least 6 months after stopping this therapy.</li><li>They are at increased risk of influenza and pneumococcal infection and should receive appropriate vaccinations regularly. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-seasonal-influenza/\">Immunizations - seasonal influenza</a> and <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-pneumococcal/\">Immunizations - pneumococcal</a> for more information.</li></ul></li><li>Provide advice on sources of information and support such as the Psoriasis Association patient leaflets on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Methotrexate.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"08d358f8-623d-4e82-8ad4-a93100c0e99a\">Methotrexate</a>, <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Ciclosporin.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"d7c99d74-92c3-435a-97ae-a93100c0e9a5\">Ciclosporin</a>, and <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Acitretin.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"697293c5-2b38-4693-8b4c-a93100c0e9b1\">Acitretin</a>, and the British Association of Dermatologists leaflet on <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=124&itemtype=document\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"ef2b7b62-49b0-4ccd-bfe8-a93100c0e9c5\">Treatments for moderate or severe psoriasis</a>.</li></ul><h5>Biologic therapy</h5><ul><li>Tumour necrosis factor (TNF)-alpha inhibitors such as adalimumab, etanercept (both given by subcutaneous injections), and infliximab (given by intravenous infusion) are indicated for the treatment of moderate to severe chronic plaque psoriasis. More recently, the monoclonal antibody ustekinumab has also been licensed for use.</li><li>These are generally used after phototherapy when conventional systemic therapies have been ineffective, are not tolerated, or are contraindicated.</li><li>Ensure the person is aware:<ul><li>About the possible effects of therapy during conception and pregnancy, and ensure the person is using effective contraception during and after treatment.</li><li>That live vaccines are contraindicated, and these vaccines should only be given before the start of specialist treatment, or else postponed for at least 6 months after stopping this therapy.</li><li>They are at increased risk of influenza and pneumococcal infection and should receive appropriate vaccinations regularly. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-seasonal-influenza/\">Immunizations - seasonal influenza</a> and <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-pneumococcal/\">Immunizations - pneumococcal</a> for more information.</li></ul></li><li>Provide advice on sources of information and support such as the Psoriasis Association patient leaflet on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/BIOLOGICS_2016.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"7790e5ad-4bef-4130-ae68-a93100c0e9e6\">Biologics for Psoriasis and Psoriatic Arthritis</a>, and the British Association of Dermatologists leaflet on <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=124&itemtype=document\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"8ecb9fd8-566e-405c-9a6c-a93100c0e9ef\">Treatments for moderate or severe psoriasis</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Jabbar-Lopez, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Smith, 2017</a>]</p><!-- end field c653b54f-e072-434f-9f51-a80800adc72a --><!-- end item 0bb89d41-9eee-4878-b548-a80800adc246 -->","subChapters":[]},{"id":"d389477e-1898-56f2-8e65-d320e4da59e0","slug":"basis-for-recommendation-a80","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 45d9da9d-b692-4b21-a790-f33562c3075a --><h4>Basis for recommendation</h4><!-- end field 45d9da9d-b692-4b21-a790-f33562c3075a -->","summary":null,"htmlStringContent":"<!-- begin item a8029433-2974-4a9c-98b9-bf0131e031d2 --><!-- begin field c5746ce7-ace8-429a-a989-fc23cf70f46b --><p>The recommendations on referral are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], and a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>].</p><ul><li>The recommendation on arranging urgent referral to rheumatology if psoriatic arthritis is suspected is based on the fact that an early diagnosis should be made to reduce the risk of erosive and progressive joint damage and loss of function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>].</li></ul><!-- end field c5746ce7-ace8-429a-a989-fc23cf70f46b --><!-- end item a8029433-2974-4a9c-98b9-bf0131e031d2 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}